Insight into the complex regulation of CD133 in glioma

International Journal of Cancer

Volumn 128, Issue 3, 2011, Pages 501-510

  Campos, Benito ^a   Herold Mende, Christel C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CD133; glioma; hypoxia; stem like tumor cells

Indexed keywords

CD133 ANTIGEN;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; CANCER CLASSIFICATION; CANCER STEM CELL; CANCER TISSUE; CARCINOGENESIS; CELL HETEROGENEITY; GLIOMA; GLIOMA CELL; HUMAN; IMMUNOREGULATION; NERVE CELL DIFFERENTIATION; NONHUMAN; OXYGEN TENSION; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; SHORT SURVEY;

ANTIBODIES; ANTIGENS, CD; GLIOMA; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; PEPTIDES; RNA, MESSENGER; STEM CELLS;

EID: 78649900502     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25687     Document Type: Short Survey

References (58)

1. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB,. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-28.
2. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB,. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
3. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL,. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 2000; 97: 14720-5.
4. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN,. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-60.
5. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS,. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
6. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC,. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008; 14: 123-9.
7. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP,. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-15.
8. Zheng X, Shen G, Yang X, Liu W,. Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res 2007; 67: 3691-7.
9. Wu A, Oh S, Wiesner SM, Ericson K, Chen L, Hall WA, Champoux PE, Low WC, Ohlfest JR,. Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev 2008; 17: 173-84.
10. Wang J, Sakariassen PØ, Tsinkalovsky O, Immervoll H, Bøe SO, Svendsen A, Prestegarden L, Røsland G, Thorsen F, Stuhr L, Molven A, Bjerkvig R, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008; 122: 761-8.
11. Tamaki S, Eckert K, He D, Sutton R, Doshe M, Jain G, Tushinski R, Reitsma M, Harris B, Tsukamoto A, Gage F, Weissman I, et al. Engraftment of sorted/expanded human central nervous system stem cells from fetal brain. J Neurosci Res 2002; 69: 976-86.
12. Schwartz PH, Bryant PJ, Fuja TJ, Su H, O'Dowd DK, Klassen H,. Isolation and characterization of neural progenitor cells from post-mortem human cortex. J Neurosci Res 2003; 74: 838-51.
13. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW,. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 5002-12.
14. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S,. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95: 952-8.
15. Torrente Y, Belicchi M, Sampaolesi M, Pisati F, Meregalli M, D'Antona G, Tonlorenzi R, Porretti L, Gavina M, Mamchaoui K, Pellegrino MA, Furling D, et al. Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. J Clin Invest 2004; 114: 182-95.
16. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT,. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117: 3539-45.
17. Leong KG, Wang B, Johnson L, Gao W,. Generation of a prostate from a single adult stem cell. Nature 2008; 456: 804-8.
18. Bhatia M,. AC133 expression in human stem cells. Leukemia 2001; 15: 1685-8.
19. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ,. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51.
20. O'Brien CA, Pollett A, Gallinger S, Dick JE,. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-10.
21. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H,. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006; 351: 820-4.
22. Beier D, Wischhusen J, Dietmaier W, Hau P, Proescholdt M, Brawanski A, Bogdahn U, Beier CP,. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol 2008; 18: 370-7.
23. Rebetz J, Tian D, Persson A, Widegren B, Salford LG, Englund E, Gisselsson D, Fan X,. Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma. PLoS ONE 2008; 3: e1936.
24. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, De Maria R,. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 2008; 14: 8205-12.
25. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, Fang J,. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res 2008; 27: 85.
26. Corbeil D, Röper K, Hannah MJ, Hellwig A, Huttner WB,. Selective localization of the polytopic membrane protein prominin in microvilli of epithelial cells-a combination of apical sorting and retention in plasma membrane protrusions. J Cell Sci 1999; 112: 1023-33.
27. Corbeil D, Röper K, Hellwig A, Tavian M, Miraglia S, Watt SM, Simmons PJ, Peault B, Buck DW, Huttner WB,. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000; 275: 5512-20.
28. Corbeil D, Röper K, Fargeas CA, Joester A, Huttner WB,. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001; 2: 82-91.
29. Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE, Ahmadi R, Lohr J, Dictus C, Gdynia G, Combs SE, Goidts V, et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 2010; 16: 2715-28.
30. Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeilstra J, Pals ST, Mehmet H, Stassi G, Medema JP,. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 2010; 70: 719-29.
31. Karbanová J, Missol-Kolka E, Fonseca A, Lorra C, Janich P, Hollerová H, Jászai J, Ehrmann J, Kolár Z, Liebers C, Arl S, Subrtová D, et al. The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem 2008; 56: 977-93.
32. Yu Y, Flint A, Dvorin EL, Bischoff J,. AC133-2, a novel isoform of human AC133 stem cell antigen. J Biol Chem 2002; 277: 20711-16.
33. Bauer N, Fonseca A, Florek M, Freund D, Jászai J, Bornhäuser M, Fargeas CA, Corbeil D,. New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). Cells Tissues Organs 2008; 188: 127-38.
34. Florek M, Haase M, Marzesco A, Freund D, Ehninger G, Huttner WB, Corbeil D,. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 2005; 319: 15-26.
35. Son MJ, Woolard K, Nam D, Lee J, Fine HA,. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009; 4: 440-52.
36. Ogden AT, Waziri AE, Lochhead RA, Fusco D, Lopez K, Ellis JA, Kang J, Assanah M, McKhann GM, Sisti MB, McCormick PC, Canoll P, et al. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery 2008; 62: 505-14; discussion 514-15.
37. Clément V, Marino D, Cudalbu C, Hamou M, Mlynarik V, de Tribolet N, Dietrich P, Gruetter R, Hegi ME, Radovanovic I,. Marker-independent identification of glioma-initiating cells. Nat Methods 2010; 7: 224-8.
38. Pistollato F, Abbadi S, Rampazzo E, Persano L, Della Puppa A, Frasson C, Sarto E, Scienza R, D'avella D, Basso G,. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 2010; 28: 851-62.
39. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK, Fine HA,. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9: 391-403.
40. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, Squire JA, Smith A, et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009; 4: 568-80.
41. Kondo T, Setoguchi T, Taga T,. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004; 101: 781-6.
42. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ,. Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-8.
43. Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, Schwarz J, Junker M, Oefner PJ, Bogdahn U, Wischhusen J, Spang R, Storch A, et al. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 2010; 70: 2030-40.
44. Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR, Gillespie GY,. CD133 is a marker of bioenergetic stress in human glioma. PLoS ONE 2008; 3: e3655.
45. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82.
46. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB, Rich JN,. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15: 501-13.
47. McCord AM, Jamal M, Shankavaram UT, Shankavarum UT, Lang FF, Camphausen K, Tofilon PJ,. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 2009; 7: 489-97.
48. Blazek ER, Foutch JL, Maki G,. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007; 67: 1-5.
49. Platet N, Liu SY, Atifi ME, Oliver L, Vallette FM, Berger F, Wion D,. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 2007; 258: 286-90.
50. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, Pollack IF, Park DM,. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009; 28: 3949-59.
51. Jensen RL,. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 2009; 92: 317-35.
52. Oliver L, Olivier C, Marhuenda FB, Campone M, Vallette FM,. Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy. Curr Mol Pharmacol 2009; 2: 263-84.
53. Holmquist-Mengelbier L, Fredlund E, Löfstedt T, Noguera R, Navarro S, Nilsson H, Pietras A, Vallon-Christersson J, Borg A, Gradin K, Poellinger L, PÃhlman S,. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 2006; 10: 413-23.
54. Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, Tamura D, Aomatsu K, Tamura T, Yamada Y, Saijo N, Nishio K,. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 2009; 69: 7160-64.
55. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, Modrusan Z, Nacu S, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010; 17: 3-375.
56. Ogasawara MA, Zhang H,. Redox regulation and its emerging roles in stem cells and stem-like cancer cells. Antioxid Redox Signal 2009; 11: 1107-22.
57. Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, Natsugoe S, Aikou T, Takao S,. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008; 98: 1389-97.
58. Horst D, Kriegl L, Engel J, Kirchner T, Jung A,. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008; 99: 1285-9.